Histamine Pharmacogenetics in Children With Atopic Dermatitis
6 Months
5 Years
Both
Dermatitis, Atopic
Trial Information
Histamine Pharmacogenetics in Children With Atopic Dermatitis
Atopic dermatitis (AD) is a common condition in the pediatric population, affecting an
estimated 15% of all children greater than 18 months of age in the United States. It is now
recognized that AD is a disease of significant heterogeneity with respect to both disease
severity and response to conventional pharmacologic therapies. With the recognition of this
variability comes the understanding that, as with many other allergic disease, there exist
many specific disease phenotypes that ultimately govern response to pharmacologic
intervention. The characterization of these unique phenotypes and their associated biologic
mediators is therefore of critical therapeutic importance in the development of disease and
patient-specific treatment strategies.
The long term objective of this research is to explore the effects of genetic, environmental
and developmental influences on the primary determinants of histamine action in atopic
children and to identify potential histamine "haplotypes" that may be predictive of disease
severity, progression and/or response to therapy.
The primary hypothesis is the presence of HNMT T314 allele and /or slow acetylation genotype
is associated with childhood atopic dermatitis.
Inclusion Criteria:
- Caucasian, Hispanic and African American children ages 6 months to 5 years with a
diagnosis of atopic dermatitis within the last 12 months will constitute the
candidate pool for enrollment into the study group. The diagnosis of atopic
dermatitis will be determined by the presence of at least 3 major diagnostic features
(i.e., pruritis, rash,relapsing-remitting presentation, family history or atopy) in
addition to at least 3 minor features (including but not limited to xerosis, elevated
serum IgE, ocular involvement, food allergy). Healthy Caucasian, Hispanic and
African American children within the same age range will comprise the pool for
enrollment into the control group.
Exclusion Criteria:
- Any child with atopic dermatitis who has a documented history of asthma or
bronchospasm or who is currently receiving treatment for either of these conditions
will be excluded. Any control subject who has asthma or positive family history of
allergy or atopic disease in a first-degree relative (biological mother, father or
siblings) will also be ineligible for enrollment.
Type of Study:
Observational
Study Design:
Observational Model: Case Control, Time Perspective: Retrospective
Principal Investigator
Mary Jayne Kennedy, Pharm D.
Investigator Role:
Principal Investigator
Investigator Affiliation:
Virginia Commonwealth University
Authority:
United States: Federal Government
Study ID:
PPRU 10744
NCT ID:
NCT00277433
Start Date:
June 2004
Completion Date:
December 2009
Related Keywords:
- Dermatitis, Atopic
- Atopic Dermatitis
- Eczema
- Genetics
- Histamine
- Dermatitis
- Dermatitis, Atopic
Name | Location |
|---|---|
| Children's National Medical Center | Washington, District of Columbia 20010-2970 |
| Children's Mercy Hospital | Kansas City, Missouri 64108 |
| Arkansas Children's Hospital | Little Rock, Arkansas 72202-3591 |
| University of California at San Diego | La Jolla, California 92093 |
| Kosair Charities Pediatric Clinical Research Unit | Louisville, Kentucky 40202 |
| Wayne State University/Children's Hospital of Michigan | Detroit, Michigan 48201 |
| Baylor College of Medicine/Texas Children's Cancer Center | Houston, Texas 77030 |
